Simulations Plus (SLP) Stock Overview
Develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
SLP Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Simulations Plus, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.91 |
| 52 Week High | US$44.27 |
| 52 Week Low | US$12.85 |
| Beta | 0.83 |
| 1 Month Change | -31.87% |
| 3 Month Change | -60.51% |
| 1 Year Change | -69.96% |
| 3 Year Change | -78.87% |
| 5 Year Change | -80.80% |
| Change since IPO | 838.91% |
Recent News & Updates
Recent updates
Simulations Plus: Still Positioned For FDA In‑Silico Trend Despite Near‑Term Headwinds
Jul 17Simulations Plus, Inc.'s (NASDAQ:SLP) Stock Retreats 36% But Earnings Haven't Escaped The Attention Of Investors
Jun 13
Are Investors Undervaluing Simulations Plus, Inc. (NASDAQ:SLP) By 28%?
May 07Simulations Plus: Benefiting From FDA Modernization And AI
Apr 16Simulations Plus, Inc.'s (NASDAQ:SLP) 25% Jump Shows Its Popularity With Investors
Apr 13Why Investors Shouldn't Be Surprised By Simulations Plus, Inc.'s (NASDAQ:SLP) 29% Share Price Surge
Feb 08Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't Ideal
Jan 08We Think Simulations Plus' (NASDAQ:SLP) Healthy Earnings Might Be Conservative
Nov 07
Biosimulation Innovations And Tactical Acquisitions To Boost Drug Development Growth
Integration and expansion into new markets drive revenue growth and improved profitability through increased efficiencies and enhanced offerings.Simulations Plus: Declining Margins Are A Problem
Aug 22Simulations Plus: Steady Growth, But What About The Margins?
Jul 10Simulations Plus: Reliance On Consulting And Acquisitions Creates Doubts
May 14Why We're Not Concerned About Simulations Plus, Inc.'s (NASDAQ:SLP) Share Price
Mar 29Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't Ideal
Feb 09Simulations Plus: Questionable Whether It Will Benefit Or Be Hurt By Generative AI
Feb 01We Like Simulations Plus' (NASDAQ:SLP) Earnings For More Than Just Statutory Profit
Jan 12Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't Ideal
Nov 06Estimating The Intrinsic Value Of Simulations Plus, Inc. (NASDAQ:SLP)
Sep 06Shareholder Returns
| SLP | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | -26.4% | -0.8% | -0.09% |
| 1Y | -70.0% | 33.2% | 12.4% |
Return vs Industry: SLP underperformed the US Healthcare Services industry which returned 29% over the past year.
Return vs Market: SLP underperformed the US Market which returned 10% over the past year.
Price Volatility
| SLP volatility | |
|---|---|
| SLP Average Weekly Movement | 12.8% |
| Healthcare Services Industry Average Movement | 8.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: SLP's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SLP's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 245 | Shawn O'Connor | www.simulations-plus.com |
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
Simulations Plus, Inc. Fundamentals Summary
| SLP fundamental statistics | |
|---|---|
| Market cap | US$261.05m |
| Earnings (TTM) | -US$63.19m |
| Revenue (TTM) | US$80.38m |
Is SLP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLP income statement (TTM) | |
|---|---|
| Revenue | US$80.38m |
| Cost of Revenue | US$37.18m |
| Gross Profit | US$43.20m |
| Other Expenses | US$106.40m |
| Earnings | -US$63.19m |
Last Reported Earnings
May 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.14 |
| Gross Margin | 53.75% |
| Net Profit Margin | -78.62% |
| Debt/Equity Ratio | 0% |
How did SLP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/16 16:14 |
| End of Day Share Price | 2025/07/16 00:00 |
| Earnings | 2025/05/31 |
| Annual Earnings | 2024/08/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Simulations Plus, Inc. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Larsen | BTIG |
| Dane Leone | CGS International |
| Constantine Davides | Citizens JMP Securities, LLC |